Insider Selling: OmniAb, Inc. (NASDAQ:OABI) CFO Sells 15,526 Shares of Stock

OmniAb, Inc. (NASDAQ:OABI) CFO Kurt A. Gustafson sold 15,526 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total transaction of $50,304.24. Following the transaction, the chief financial officer now owns 212,720 shares of the company’s stock, valued at $689,212.80. This represents a 6.80 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

OmniAb Trading Down 0.6 %

OABI traded down $0.02 on Wednesday, reaching $3.20. The stock had a trading volume of 576,116 shares, compared to its average volume of 413,324. The business’s 50-day moving average price is $3.69 and its two-hundred day moving average price is $4.07. OmniAb, Inc. has a 12-month low of $3.16 and a 12-month high of $6.55. The company has a market cap of $451.90 million, a P/E ratio of -5.16 and a beta of -0.10.

Hedge Funds Weigh In On OmniAb

Several institutional investors and hedge funds have recently modified their holdings of OABI. Barclays PLC boosted its position in OmniAb by 321.5% during the third quarter. Barclays PLC now owns 143,215 shares of the company’s stock worth $606,000 after purchasing an additional 109,236 shares in the last quarter. FMR LLC lifted its position in shares of OmniAb by 10.6% during the 3rd quarter. FMR LLC now owns 138,813 shares of the company’s stock valued at $587,000 after buying an additional 13,324 shares in the last quarter. Atria Investments Inc purchased a new stake in OmniAb in the 3rd quarter worth $148,000. Murchinson Ltd. purchased a new stake in OmniAb in the 3rd quarter worth $4,230,000. Finally, State Street Corp lifted its holdings in OmniAb by 1.7% during the third quarter. State Street Corp now owns 2,031,676 shares of the company’s stock valued at $8,594,000 after purchasing an additional 34,654 shares in the last quarter. Hedge funds and other institutional investors own 72.08% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Benchmark reissued a “buy” rating and issued a $8.00 price objective on shares of OmniAb in a report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of OmniAb in a report on Thursday, November 14th.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.